Rheumatoid arthritistherapeutics market expected to Grow at 4.2% by 2031, Rheumatoid arthritis is an autoimmune, inflammatory disease that causes chronic pain, swelling and loss in the functioning ability of joints. It occurs when the immune system attacks the synovium – the inner lining of membranes that surrounds the joints. In some patients, the antibodies also damage some body systems including the skin, heart, eyes, lungs and blood vessels. Prevalence of rheumatoid arthritis widely varies in different geographic region, the lowest rates is observed in the Asian countries and higher rates among some American populations. According to Centers for Disease Control and Prevention (CDC), the prevalence of rheumatoid arthritis in the United States is approximately 0.6% of total population. Generally rheumatoid arthritis affects at twice the rate in women as compared to men. Mostly rheumatoid arthritis affects among those in their sixties. According to World Health Organization (WHO), prevalence varies between 0.3% and 1% and is more common in developed countries.

There are many approaches used in treatment of rheumatoid arthritis such as drug therapy, rehabilitation and physical therapy, nutrition, psychosocial interventions, alternative treatment approaches and surgical interventions. Global rheumatoid arthritis therapeutics market is segmented on the basis of drug type such as Non-biologics and Biologic agent (Adalimumab, Infliximab and others). Non-biologics is sub-segmented as NSAIDs (Diclofenac, Ibuprofen and others), Disease-modifying antirheumatic drugs (DMARDs) (Methotrexate, Leflunomide and others) and steroids (Cortisone or Prednisone). Biologics, DMARDs and steroids slows the joint damage from rheumatoid arthritis, while NSAIDs only reduces pain and inflammation. Biologics are used in treatment of moderate to severe rheumatoid arthritis when patient does not respond adequately to other treatments.

The major growth drivers of the global rheumatoid arthritis therapeutic market includes, increase in geriatric population that will increase prevalence of rheumatoid arthritis, launch of novel therapeutic agents, higher prevalence rates among some American native populations and insurance coverage for high cost specialty drugs in developed countries. However, factors such as, inadequate insurance coverage for certain drugs in developing countries, non-availability of the treatment and patent expiration of some blockbuster drugs are the main restraints for the rheumatoid arthritis therapeutic market.

Some key Players in global rheumatoid arthritis therapeutic market are, Pfizer Inc., Bristol Myers Squibb, Abbvie Inc., Ucb Pharma, Genentech, Janssen Pharmaceutical, Immunex Corp., Medac Pharma, Mallinckrodt, Novartis, Astrazeneca Pharma, MedImmune, Biogen, Eli Lilly And Company, Astellas Pharma, Roche, Vertex Pharmaceuticals And Other Notable Players.

This report offers:

• An overview of the global markets for Rheumatoid Arthritis Therapeutics.
• Qualitative assessment tools such as market drivers, challenges and future prospects.
• Market competition scrutiny tools such as market share analysis, fractal map assessment.
• Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics.
• A general overview of the industry structure.
• Company profiles highlighting key information about the major players operating in the global rheumatoid arthritis therapeutics market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Rheumatoid Arthritis Therapeutics market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Rheumatoid Arthritis Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Rheumatoid Arthritis Therapeutics market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Rheumatoid Arthritis Therapeutics market?
• Which is the largest regional market for Rheumatoid Arthritis Therapeutics market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Rheumatoid Arthritis Therapeutics market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Rheumatoid Arthritis Therapeutics market worldwide?